Director of Sales, Spain & Portugal
- Seagen
-
28014 Madrid
-
20.03.2021
DescriptionSummary: Seagen recently got the TUKYSA (tucatinib), a tyrosine kinase inhibitor (TKI), approved by EMA for HER2+ metastatic breast cancer patients in Europe. Currently, Seagen is buildi...
Leer más...